Audited Financial Results for the quarter and year ended 31st March, 2026.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.5 pts more than Nifty Microcap 250 and 8.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kwality Pharmaceuticals reported strong FY26 results with consolidated revenue of Rs 503 crore, up 36% from Rs 370 crore in FY25. Q4 FY26 saw its strongest-ever quarterly topline of Rs 157.11 crore, growing 35.8% YoY. PAT jumped 69% to Rs 67.34 crore from Rs 39.80 crore, with margins expanding 260 basis points to 13.4%. EBITDA margins improved 200 basis points to 24%, driven by better product mix and regulated market growth. The company also received an ICRA credit rating upgrade to BBB+ from B+. An exceptional item of Rs 82.94 lakhs was recorded due to new labour code implementation affecting gratuity liabilities. Working capital pressures from elevated debtor days (208 days) led to negative operating cash flow of Rs 16.59 crore for the year.
The stock shows strong operational momentum with near-70% PAT growth and margin expansion, signaling improved profitability quality. The credit rating upgrade and clean audit opinion are positive signals, though the negative operating cash flow and high debtor days warrant monitoring of working capital management.